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1 Executive Summary  
Background  
Waltham Forest Borough Council and Waltham Forest Clinical Commissioning Group have commissioned 
the Institute for Health and Human Development based at the University of East London (UEL) to conduct 
an evaluation of the social prescribing service in Waltham Forest. As agreed in the document submitted to 
the funder, this final report presents and discusses the results from the evaluation of health outcomes, the 
process of development of the service and social return on investment for the period between July 2016 
and May 2017.  
 
Methodology  
The evaluation is based on a mixed methods approach which includes the following:  
A prospective cohort study:  we captured health and social changes in the population of social prescribing 
users over a four month period via a telephone survey conducted by researchers from Waltham Forest 
council. We collected data on health, well-being, quality of life, mental well-being, patient activation, 
demographic profile and use of health and social services. The information collected by this cohort study 
also fed into the development of a social return on investment assessment.  
Process evaluation: this discusses the key learning to date drawing on data from social prescribing users, 
social prescribers, community organisations, and healthcare professionals.  
Qualitative study of social prescribing participants: a range of qualitative interviews with social prescribing 
users was also conducted to document experiences with the intervention.  
 
Key Results 
In terms of patients’ outcomes, social prescribing has had a positive impact on respondents:  
 Social prescribing users at follow up (N=48) recorded positive changes in all indicators (mental well-
being, health, well-being, quality of life, and patient activation) with the last three of these being 
statistically significant. Health outcomes improved from a very low starting position, thus more work 
needs to be done to ensure that users achieve satisfactory levels of health and well-being. 
 The Social Return on Investment (SROI) showed that for £1 invested in the social prescribing service in 
Waltham Forest, the expected return to society could range between £1.09 and £1.92. This is 
considered a good investment, despite being below the average reported by other studies (£1:£2.3). 
 Respondents also reported large improvements in their concerns toward Housing, Practical Support, 
Work & Finance. 
 Although qualitative interviews with users were not so positive, this was mainly related to the lack of 
CVS offer and long waiting to access CVS services rather than an inherent problem with the rationale 
for social prescribing.  
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In terms of the effective functioning of the pathway, some benefits included:  
 Good overall relationship with GP practices. 
 Some good links with CVS were also established and more links were being built.  
 
Recommendations 
However, in considering the future design of the model, it is worth reflecting on the following 
recommendations and consider the suggested social prescribing model (sec. 7.2 and fig.8):  
1. Build further links and invest in the development of the community and voluntary sector (CVS) 
which are indispensable for the success of any models of social prescribing. The evaluation 
identified gaps in service provision, lack of funding for delivery, and skills gaps as key issues. 
2. The role of social prescribers is key to the success of social prescribers. The evaluation found an 
inadequate number of social prescribers in relation to the high number of referrals and 
stakeholders had different views about their role (light touch only phone service versus in-depth 
face-to-face support). The design of the social prescribing model needs to consider this further. 
3. SP has been more effective at tackling practical problems (e.g. work& finance) than mental health 
problems which require behaviour change. An alternative delivery model may be considered and 
has been discussed in sec.7.2. 
4. The integration with other Better Care Together Programme may be discussed further as there are 
several challenges with referring patients to self-care pharmacists and/or physician associates. 
5. Referral criteria may also be explored further. There were some instances where patients referred 
presented acute health problems which did not seem suitable for social prescribing support but 
required instead clinical treatment in secondary care.  
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2 Introduction 
The National Health Service in the UK (NHS) is facing a wide range of challenges, particularly in the context 
of primary care provision. These include: (i) growing pressure on GP practices which is partly driven by the 
number of patients who frequently attend their GP surgery with medically unexplained symptoms. About, 
20% of patients consult their GPs for problems that are primarily social rather than medical (Torjesen, 
2016); (ii) the rising tide of long term conditions growing by 5 million in the next ten years (DH, 2013) 
despite the 70-80% of people with long term conditions (LTCs) who could be supported to manage their 
own conditions (DH 2005); (iii) growing health inequalities which result in long-term medical conditions 
disproportionately affecting people in deprived areas (Marmot et al., 2010; Cawston, 2011; Hutt and 
Gilmour, 2010). 
 
In an attempt to seek solutions to these problems, the concept of social prescribing holds significant 
promise. Social prescribing ‘enables healthcare professionals to refer patients to a link worker, to co-design 
a non-clinical social prescription to improve their health and well-being’ (SPN, 2016; p.19). 
 
The NHS Five Year Forward View (NHS,2014) recognises social prescribing as an important model for the 
future of the NHS and is described by the current Health Secretary as an intervention that helps the NHS to 
take a ‘more holistic view of what it takes to address people’s medical problems than it did before’ (GP 
online, 2014). In addition, social prescribing has the potential to help deliver other government priorities in 
the field of health such as: the merger of health and social care, developing and delivering health at the 
community level, and delivering a patient centred approach which supports patients to access community 
activities thereby empowering the patient to decide what is right for them and their personal 
circumstances.  
 
In this context, the Institute for Health and Human Development based at the University of East London 
(UEL) has been commissioned by Waltham Forest Borough Council (WFBC) and Waltham Forest Clinical 
Commissioning Group (WFCCG) to conduct an evaluation of the social prescribing service in Waltham 
Forest. This includes health outcomes, qualitative interviews, a process, and an economic evaluation (see 
methodology section 4).  
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3 Description of the Social Prescribing 
Service in Waltham Forest  
This section describes the key characteristics of 
the social prescribing pilot in Waltham Forest and 
discusses how social prescribing fits into the 
wider set of health interventions available in the 
borough. The social prescribing (SP) pilot was 
officially launched on 14th June 2016 and is 
schedule to run for 18 months until the end of 
Dec 2017. Referrals into the service started in July 
2016. 
The main aims of the social prescribing pilot 
scheme1 are to: 
 Facilitate access to a range of support 
services that will enable individuals to 
significantly improve their health and 
wellbeing. 
 Increase the role of the CVS (Community and 
voluntary Sector) in the provision of services 
and evaluate aspects of the service model 
prior to wider adoption across the borough. 
 Release specialist capacity across the 
system, so that individuals with the most 
intense health and social care needs can 
receive the care they require despite funding 
constraints. 
 Increase ‘whole system’ efficiency by 
preventing deterioration in the service user’s 
condition and by reducing duplication of 
care between organisations and professions. 
 Provide ‘seamless’ care by placing the 
service user at the centre of decision-making 
                                                          
1 Invitation to Quote (ITQ) Social Prescribing 
Evaluation 
and designing packages of interventions 
around their needs irrespective of provider. 
The SP pilot includes patient referrals from 
Healthcare professionals (GP practices and Adult 
and Social Care department within the council) to 
two social prescribers based at Waltham Forest 
Borough Council (WFBC) who are responsible for 
contacting patients over the phone, discussing 
their needs and aspirations and recommending a 
range of solutions available in the statutory or 
community sector. Healthcare professionals can 
refer patients with a wide range of health and 
non-health issues including social and economic 
concerns.  
As part of the referral, a form was filled in by 
healthcare professionals and sent to social 
prescribers based at WFBC. The original plan was 
for Social Prescribers to make three phone calls 
to each patient: first phone call to understand 
clients’ needs and aspirations, second phone call 
to enable social prescribers to recommend a 
package of support from statutory or community 
organisations and a third phone call after eight 
weeks to assess the patient progress in accessing 
support services.   
SP is part of the Better Care Together Programme 
which has been running in Waltham Forest for 
the last three years or so, and involves the joint 
working of different partners including LBWF, 
CCG, NELFT, and CVS to deliver healthcare. In the 
early years, this programme focussed on the top 
3-4% of the most acute cases in the borough who 
were supported by community matrons with 
clinical expertise and aimed at stabilising the 
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patient and avoid potential crisis. The aim of 
social prescribing is to tackle health issues of 
population with less severe issues primarily 
through early intervention, prevention and self-
help.  
 
In the wider context of social prescribing pilots 
across the UK, Waltham Forest SP is unique as it 
is only delivered over the telephone. Most SP 
pilots offer face to face sessions with a social 
prescriber or are a mix of telephone and face to 
face.  
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4 Methods 
The aims, objectives and study design of the evaluation are described in this section.  
 
4.1 Aims and objectives of the evaluation 
The main aims of this evaluation were to assess the following:  
 The impact of the social prescribing pilot on the changes in patients’ health (outcome evaluation);  
 The process of development of the pilot and how it integrates with other local systems (process 
evaluation) 
 Patient satisfaction (service satisfaction) 
 The social return on investment, if the programme is continued 
 
The objectives of this evaluation were to collect, and/or analyse a range of information on the following: 
- Analyse monitoring information on the social prescribing pathway: sources of referral (e.g. GP 
surgeries, Adult and Social care), number of patients supported throughout the pathway, number 
of social prescribers involved, number and types of community support organisations involved; 
- Collect patients’ information about the health, well-being, quality of life, mental well-being, 
activation, demographic profile and healthcare service use;   
- Perceptions of patients using the service at different levels of involvement in the social prescribing 
pathway 
 
4.2 Study design  
We use a mixed method approach to investigate SP in Waltham Forest including a prospective cohort 
study, qualitative interviews, a process evaluation and an economic evaluation. The study started in August 
2016 and will be completed in May 2017. The methodology for each of these is described below. 
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Table 1: Summary of Evaluation design   
 
 
 
Type of 
evaluation 
Themes Method of data collection 
Cohort 
study 
To capture changes in participants’ health outcomes 
  Demographic characteristics of 
participants 
 The key concerns of respondents at 
baseline and follow up 
 Changes in quality of life, wellbeing, 
health, mental well-being and levels of 
activation over a four month period 
  
 
Telephone survey with the same population at 
baseline (Aug – Dec 2016; N=100) and four months 
follow up (Jan- May 2017; N=48).   
 Health related measures: General Health, 
wellbeing (Measure Yourself Concerns and 
Wellbeing), quality of life (EQ-5D-3L), mental 
well-being (Warwick Edinburgh Mental Wellbeing 
Scale), Patient Activation (Patient Activation 
Measure).  
 Demographic details: gender, age, ethnicity, living 
arrangements, employment status and 
educational level. 
 Service use measures: A&E attendance, GP visits, 
volunteering, skills training, community activity 
attendance and use of local council support 
services. In the follow up we will also be asking 
questions about the specific use of social 
prescribing services including the Citizen Advice 
Bureau, befriending, mental health support, lunch 
clubs, and transport.   
Process 
evaluation 
To capture opinion of stakeholders including participants to inform the future development of the 
intervention 
 Experience of participants 
 Users: experience at different stages of the 
pathway (HCP, social prescriber, TSO) 
 Unintended effect of intervention 
 Physical health, social networks, emotional 
well-being 
 Demographic details 
 
Semi-structured telephone interviews with 
participants who have been referred by social 
prescribers and attended community organisations 
and those who have been referred by social 
prescribers but did not attend community 
organisations  
 Experience of stakeholders 
All stakeholders: 
 Barriers and enablers  
 Integration in existing health economy 
 Strategies for referrals (social prescribers 
only) 
 Feedback to HCPs 
From social prescribers: 
 Number of sessions, contact time and 
details of user referrals 
 Number and details of Did Not Attend 
(between social prescriber and CVS) 
Focus groups with community organisations and 
social prescribers;  online survey with community 
organisations and healthcare professionals; 1-2-1 
telephone interviews with social prescribers, CCG 
staff, local authority and community organisations 
Economic 
evaluation  
Social return on investment: this measures the return to society from a financial investment into 
social prescribing 
 Financial analysis of health outcomes and 
healthcare resource use. Analysis of 
attribution, drop-off, displacement, and 
deadweight (sec. 5.3.3 for more details) 
From Cohort study: baseline and follow up data on 
healthcare use (GP, A&E visits), use of services, use of 
community activities, employment, and volunteering. 
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4.2.1 A prospective cohort study 
A prospective cohort study was conducted to to understand key changes to the health and social outcomes 
of SP users. We collected data from the same population at two points in time using a structured 
questionnaire, baseline (Aug-Dec 2016) and four months follow up (Jan-May 2017). Key measures collected 
are reported in  
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Table 1. Baseline (n=100) and follow up (N=48) data collection was undertaken over the phone by three 
Waltham Forest Borough Council researchers independently employed from the delivery of the social 
prescribing service. In most cases, individuals referred by healthcare professionals received a telephone call 
prior to their contact with social prescribers in order to collect an accurate baseline measure. A small 
number of participants were sent a postal questionnaire.  
 
4.2.2 Users’ experience of the social prescribing service in Waltham Forest 
 
We conducted qualitative interviews with individuals who were referred by their healthcare professionals 
to the social prescribing service to capture more detailed information about the quality of the service. In 
order to account for different opinions we attempted to stratify respondents as follows: (i) those who 
attended at least three sessions whom are defined as having completed SP (15); (ii) those who were 
referred by SPs but attended no sessions with the community/voluntary or statutory sector (6). In practice, 
we were able to interview different groups of participants, but not by selecting them beforehand. We 
selected a random sample of participants, some of whom had not been able to access community 
organisations and therefore fell into the second group. We completed nine qualitative telephone interviews 
and collected information about the background of SP users, their experience with healthcare 
professionals, social prescribers, and community/statutory services. This enabled us to put into context 
some of the results from the prospective cohort study and provide further information for the 
development of the service (see sec. 1.1.1 for results and 6.1.2 for discussion). Some 21 interviews were 
originally planned but in agreement with the commissioner of the evaluation, we stopped at nine 
interviews because information from an additional respondent was very similar to information received 
from previous respondents (also called saturation) and decided to concentrate on administering two online 
surveys to collect further data from community organisations and healthcare professionals.  
  
 
4.2.3 Process evaluation  
The process evaluation collected information about the different stages of implementation of the SP pilot 
in Waltham Forest. This included information from healthcare professionals to social prescriber and from 
these to community and statutory services. We also gathered information about referral integration by 
interviewing stakeholders involved in the setting up, management and implementation of the SP pilot. We 
conducted semi-structured telephone interviews with stakeholders involved in the strategic development 
of the pilot, one focus group with social prescribers, one focus group with community organisations, one 
online survey with healthcare professionals and an online survey with community organisations (see 5.2.4 
for results and 6.1.2 for a discussion of results). We completed all the interviews we set out to do, except 
one interview with a GP. However, in addition to the initial specification, we conducted two online surveys, 
one with GPs and one with community organisations.  
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4.2.4 Economic Evaluation 
We followed an established and recognised methodology (Cupitt, 2009) to conduct a Social Return on 
Investment (SROI) analysis (sec. 5.3). This enabled us to illustrate the benefit to society from each £1 invested 
in the social prescribing pilot. We used a range of published information to estimate the financial values of 
the following outputs and outcomes: GP consultation rates, A&E attendance, volunteering, employment, 
mental well-being, quality of life and patient activation measure. As part of the SROI assessment framework, 
we calculated deadweight, attribution, displacement, and drop off. Finally, we produced a sensitivity analysis 
which gave us a likely range for the SROI ratio (5.5.2).  
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5 Results 
In this section, we present the results from our quantitative survey with social prescribing users (cohort 
study), results from our qualitative interviews with SP users and other stakeholders (process evaluation), 
and results from the assessment of social return on investment (economic evaluation).  
 
5.1 Prospective cohort study 
With the cohort study we were able to follow a sample of people over a four month period to assess 
changes to their demographic profile, health outcomes, activation, and other social aspects such as 
employment, volunteering, and training.   
 
5.1.1 Descriptive analyses of participant characteristics 
The demographic profile described here includes a total of 100 patients at baseline and 48 at follow up, four 
months later. Changes in health outcomes and other variables draw on baseline and follow up data collected 
from these 48 patients. Table 1 shows that just over two out five of the baseline respondents (44%) are aged 
between 45 and 64 and 63% are female (Table 2). This trend continued at follow up with even a larger 
proportion of respondents being in the 45 to 54 years old age group (54%).  
 
Four out 10 respondents were white, and four out 10 lived alone. Most of the respondents (91%) spoke good 
or fluent English and 49% of them were still in full-time education at age 16. A considerable number of 
respondents were not in paid employment (65%). More than half of these (33% of total) could not work due 
to sickness suggesting that some of the most marginalised groups are being referred to the Waltham Forest 
SP service. The profile of respondents at follow up was mostly similar to baseline, with the exception of work 
status. At follow up many more respondents were ‘unable to work due to sickness’ in relation to the baseline 
sample which had a large proportion of retired.  
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Table 2: Demographic details of SP users at baseline and four months follow up 
 
Profile 
 
Baseline (N=100) 
 
Follow up (N=48) 
Age groups (years) % 
18-24 
25-44 
45-64 
>=65 
Unspecified 
 
2 
31 
44 
21 
2 
 
2 
29 
54 
13 
2 
Gender % 
Male 
Female 
Unspecified 
 
34 
63 
3 
 
40 
58 
2 
Ethnicity % 
White 
Black 
Asian  
Mixed/Other 
Unspecified 
 
44 
19 
19 
5 
13 
 
46 
19 
21 
6 
8 
Living arrangements % 
Alone 
With others 
Unspecified 
 
38 
59 
3 
 
38 
62 
0 
Language fluency % 
Fluent 
Good 
Below average or poor 
Unspecified 
 
72 
19 
7 
2 
 
73 
17 
2 
8 
Work status % 
Employed 
Unemployed and looking for work 
Unable to work due to sickness 
Looking after your family, in education and other 
Retired 
 
14 
20 
33 
12 
21 
 
10 
23 
42 
12 
13 
Age left full time education % 
None formal education 
Up to age 16 
 Age 17 and upwards 
Still in full-time education and other 
 
2 
45 
49 
4 
 
0 
48 
48 
4 
 
 
5.1.2 Changes in patient concerns over four months  
Baseline evaluation data was collected via a telephone survey from 100 respondents who had used 
Waltham Forest’s social prescribing service. Some 87 respondents reported their primary concern and 76 
their secondary concern at the time of referral. The bar chart below shows that the most common primary 
concern of users was ‘work or finances’ (including issues to do with benefits). This was followed by 
problems with physical health and then mental health issues. The most common secondary concern was 
mental health, with physical health second and work and financial concerns came third. 
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Figure 1: Presenting concerns of service users 
 
 
 
At follow-up 48 service users reported their primary concern and 41 a secondary concern. The biggest improvement 
improvement for primary concerns was in housing related issues where there was a reported average 2.6 point 
point improvement of symptoms per individual (Figure 2). This was followed by practical support with a 1.75 
reported improvement in symptoms and work and finance with a 1.43 point reported average improvement in 
symptoms. There were only very small reported improvements in physical and mental health symptoms and the 
isolation group showed no improvement at all. The data for concern 2 revealed that ‘practical support’ recorded the 
biggest improvement in reported severity of 5 points on average per individual ( 
Figure 3). Mental health showed the second biggest improvement of 2.75 points per individual. This could 
indicate that the alleviation of primary, more practical concerns like housing and finance, lead to improved 
mental wellbeing for those individuals.  
Figure 2: Improvement in perceived symptoms for concern 1 
 
 
 
Figure 3: Improvement in perceived symptoms for concern 2 
0
5
10
15
20
25
30
Primary and secondary concerns of users referred to Waltham 
Forest's social prescribing service
Concern 1 Concern 2
0
1
2
3
Housing Work &
finance
Practical
support
Physical
health
Mental
health
Isolation
Average improvement in severity of symptoms for each 
individual (concern 1) 
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5.1.3 Changes in health outcomes between baseline and follow up 
Respondents showed an improvement in all health outcomes including general health, well-being, quality 
of life and mental well-being (table 2). The most marked improvements were observed in relation to well-
being and quality of life.  
 
Table 3: SP users’ change in health profile at baseline and follow up 
 
 
Measure 
 
 
Scale 
 
Baseline (N=100) 
 
Follow up (N=48) 
Mean (SD) Min; Max  Mean (SD) Min; Max  
General 
health 
Very bad to very good (on 
scale of 1 to 5) 
2.4(1.0) 1; 5 2.5 (1.1) 1; 5 
Well-being As bad as it could be to as 
good as it could be (on scale 
of 0-6) 
1.5 (1.3) 0; 6 2.0 (1.6) 0; 6 
Quality of 
life 1 
EQ5D single index value (1 
as the best health state) 
0.3 (0.3) -0.5; 0.9 0.5 (0.4) -0.2; 0.9 
Mental Well-
being 
WEMWB 7-item metric 
score (on scale of 7 to 35) 
18.3 (3.9) 7; 29.3 19.2 (3.1) 11.3; 25.0 
1 A detailed breakdown by EQ-5D dimensions and PAM levels are shown in Table 5 and  
 
 
 
 
 
 
 
 
 
0
1
2
3
4
5
Housing Work &
finance
Mobility Practical
support
Physical
health
Mental
health
Isolation Sleep
problems
Average (mean) improvement in perceived symptoms for each 
individual (concern 2)
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Figure 4.  
 
Table 4 (treatment effect) shows that improvements in well-being and quality of life are statistically 
significant, particularly in terms of ‘well-being’ with an average four points score increase. Furthermore, 
respondents experienced a statistically significantly reduction in GP visits (3 times less compared to 
baseline), but slightly increased their A&E visits over four months. Data about GP and A&E visits have been 
included in the social return on investment analysis (sec. 5.4). We were not able to control for any 
confounders such as gender, age, employment status, educational level as the sample size at follow up is 
too small and did not produce any statistically significant results.  
 
Table 4: Treatment effect of social prescribing 
 
Measure 
 
Effect of SP 
N Net change 6 
Coef. (95%CI) 
Significance 
P value 
General health 48 0.17 (-0.35; 0.69) 0.513 
Well-being 36 4.09 (3.10; 5.10) <0.001 
Quality of life (index score) 45 0.16 (0.04; 0.30) 0.013 
Mental Well-being 42 1.43 (-0.38; 3.23) 0.118 
Patient Activation score 45 4.46 (-0.90; 9.83) 0.101 
Patient activation level 45 0.7 (0.15; 1.32) 0.015 
GP visits 32 -3.09 (-5.61; -0.57) 0.018 
A&E visits 37 0.48 (0.04; 0.93) 0.033 
6 Net change refers to the difference in the average score between baseline and follow-up.  
 
More detailed analysis shows that improvements in dimensions of quality of life are particularly noticeable 
in terms of the respondents’ ability to perform ‘usual activities’ and reduction of feelings of ‘anxiety or 
depression’.  
 
Table 5: Change in quality of life  
 
EQ-5D dimension2 
 
Baseline 
(N=100) 
 
Follow up 
(N=48) 
Mobility % 
I have no problems in walking about  
I have some problems in walking about 
I am confined to bed 
 
36 
58 
4 
 
42 
56 
2 
Self-care % 
I have no problems with self-care 
I have some problems washing or dressing myself 
I am unable to wash or dress myself 
 
53 
41 
4 
 
56 
44 
0 
Usual activities % 
I have no problems with performing my usual activities  
 
18 
 
46 
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I have some problems with performing my usual activities  
I am unable to perform my usual activities 
64 
17 
50 
4 
Pain / Discomfort % 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort 
 
18 
49 
31 
 
40 
29 
29 
Anxiety / Depression % 
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
 
11 
56 
32 
 
19 
58 
19 
 
Mental well-being (Table 3) was measured through the Short Warwick Edinburgh Mental Wellbeing Scale 
(SWEMWBS) which is a validated scale of 7 items used for the measurement of mental wellbeing of the 
population aged 13 to 74. It comprises of seven positively worded statements and participants are asked to 
answer each mental wellbeing statement in the previous two weeks. Mental wellbeing refers here to 
positive states of being, thinking, behaving and feeling and is a good indicator of how people and 
populations are able to function and thrive (Putz et al 2012). Follow up analysis shows an improvement in 
mental well-being from 18.3 to 19.2 but this improvement is modest and not statistically significant.   
 
5.1.4 Levels of Patient activation 
The patient activation measure (PAM) is concerned with assessing the patient’s knowledge, skills and 
confidence for managing their health and health care (Hibbard and Gilburt, 2014). Higher levels of patient 
activation are associated with greater attendance to screenings and check-ups, and higher engagement in 
healthy behaviours like taking exercise (Tabrizi et al 2010). Moreover, higher levels of activation have also 
been associated with positive clinical outcomes for people suffering from depression, post-traumatic stress 
disorder, anxiety and schizophrenia (e.g. Cabassa et al 2013). Thus the higher the PAM score the better. The 
PAM can be divided in four levels:  
Level 1: the respondent may still believe that their nurse or doctor will ‘fix’ them.  
Level 2: the respondent may understand that they must be involved in their healthcare, but lack the 
knowledge and confidence to take care of their conditions.  
Level 3: the respondent is beginning to gain confidence to take on self-management behaviours and need 
to experience small successes to build a sense of self-efficacy and increase activation.  
Level 4: the respondent has the confidence and skills to manage their health, but may need help with 
maintaining their progress during stressful times. 
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Figure 4 shows the level of patient activation at baseline (N=96) and follow up (N=45). Although none of the 
respondents reached level 4 at follow up, almost 30% of respondents moved up from level 1 into level 2 
and Level 3 and this change is statistically significant (see Table 4). About 10% of respondents to both 
baseline and follow up experienced a two-level increase and another 10% a one-level increase in their PAM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Levels of Patient Activation at baseline and follow up (%)  
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5.2 Process evaluation 
The process evaluation had the following aims:  
 To use monitoring data to build a picture of the pilot in terms of referral numbers throughout the 
pathway, types of referral sources (e.g. GP practices), and types of community support organisations 
involved. 
 To gather information about referral integration by interviewing stakeholders involved in the strategic 
development and delivery of the pilot.  
 To assess the strengths and weaknesses of the pilot by collecting views from different types of users 
including social prescribing coordinators, public health officials at the London Borough of Waltham 
Forest and other stakeholders involved in the strategic development of the pilot.   
 
5.2.1 Number, source and reasons for referrals 
The current referral target for the period between July 2016 and December 2017 is 650 referrals to social 
prescribers. From July 2016 to end of June 2017 (one year), the service received 600 referrals, thus the 
target set is set to be exceeded as the average number of referrals per month to social prescribers is 86 
people. This target was revised down from 1,300 which was considered overoptimistic as designed for a 
high volume, low contact types of service. In practice, this was not feasible as most patients required a 
much higher level of assistance than initially envisaged.  
 
We do not have data related to the period from Jan to May 2017, so the following data are drawn from the 
interim report presented in Jan 2017 and concerning the period June to Dec. 2016. This shows that social 
prescribers were able to contact 69% of all patients referred. Of the 248 referrals received by social 
prescribers, 69% had been contacted until Dec 2016 (172 people). Following at least four attempts to 
contacting these, about 73% (126 people) were referred onto additional services. The remaining group 
(27%) was not referred as the service was either not suitable, users did not want it or they could not be 
reached. On average, 14 people per month were contacted through the Waltham Forest SP telephone 
service. 
 
Most of the referrals to social prescribers came through GP practices (63%) followed by citizen advice (19%), 
and adult and social care (8%). Given that the reasons for referral (Figure 5) are predominantly driven by 
concerns with money/debt/benefit, housing, and social isolation, individuals referred by GP practices are 
likely to be known to adult and social care and therefore are a key target for the intervention over and above 
the health component of social prescribing. This will be confirmed through further analysis and available in 
the final report.  
 
Figure 5: Referral sources  
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The analysis of reasons for referral (Figure 5) also shows that most referrals have taken place for reasons 
related to a social rather than health concerns, despite considerable mental health problems with 20% of the 
referrals due to low mood and anxiety.  
 
 
 
 
Figure 6: Reasons for referral from healthcare professional to social prescriber 
 
(*) please note that more than one reason for referral may have been included. Number of responses 502 
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Over the period (July to Dec 2016), some 126 people were referred to 158 activities delivered by a total of 
47 statutory and voluntary organisations.  These included a wide range of different services, the top five of 
which were citizen’s advice (money, benefit, or employment), housing/homeless, mobility, volunteering 
and mental health. The top support organisations involved in the assistance of social prescribing users 
included Citizen’s Advice (32%), St Mungo’s (9%), Talking Therapies (IAPT) (6%) and Significant Seams (3%). 
 
 Figure 7: top 5 most frequently referred to services by social prescribers 
 
 
5.2.2 Use of social prescribing community services  
When follow up data was collected as part of the cohort study, SP users were asked to name the services 
they attended in the previous four months, their rate of attendance, and whether they had been referred 
to such services as a result of social prescribing. It is useful to provide a broad understanding of whether 
participants who were referred by the social prescribers actually attended activities in the community or 
statutory sector. However, please note that this data does not reflect the total number of social prescribing 
referrals, but only of those who responded to both baseline and follow up survey (=43). There were also 
some inconsistencies in data collection, thus the data in Table 6 should be interpret with caution.  
 
About 88% of respondents to follow up data collection (N=43) were referred by the social prescribing pilot 
to a total of 62 community or statutory services delivered by Citizen Advice Bureau, Talking Therapies (i.e. 
IAPT), St Mungo’s, McMillan Cancer Services, and others. Some respondents were referred to more than 
one service. More than one out of three (35%; n=17) attended the community activities they had been 
referred to, particularly Citizen Advice Bureau (76% of attendees). Of the remaining number, about 10% 
were new referrals, leaving 55% of respondents who were referred but did not attend.  
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Table 6: number of respondents referred and attending community activities (N=49)(*) 
Types of services  Referrals  Attending 
Citizen Advice Bureau 23 13 
Support at Home 0 n/a 
Talking Therapies 11 1 
Lunch/social clubs 0 n/a 
St Mungo’s 10 n/a 
Others 19 3 
Total  63 17 
(*) this only analyses the number of respondents who were referred and attended community 
organisations. It does not represent the total number of people who were referred as part of social 
prescribing. 
 
 
5.2.3 Views from Social Prescribing users: 
qualitative interviews 
Qualitative interviews with users had the 
following aims:  
 to understand their experience of the social 
prescribing service and the strengths and 
weaknesses of the pilot from users’ 
perspectives;   
 to explore users’ background to understand 
further how to assist them more effectively in 
the future 
 
Nine participants took part in qualitative 
telephone interviews describing their experiences 
of the service. The number of participants 
interviewed was fewer than originally planned 
due to difficulties making contact with them and 
a request to divert resources into the 
development of two online surveys. Almost all of 
the respondents were unsure what social 
prescribing was and needed some prompting to 
relate it to the calls they had received from the 
Waltham Forest social prescribing team. 
 
Participant 1 (Afro-Caribbean, middle-aged, 
female) was very unhappy with her experience of 
the social prescribing service, her initial concerns 
had been regarding physical problems although 
homelessness was also an issue. She had been 
referred onto an organisation and was expecting 
to hear back from them but had heard nothing 
for 8 weeks.  
 
Participant 2, (White British, middle-aged, 
female) was helped by a lady (she couldn’t 
remember names) to apply for free prescription 
charges. While she was pleased with the help she 
had received in sourcing and filling out the form, 
she was unclear as to whether this support was 
as a result of the social prescribing service or a 
separate interaction with a health professional. 
 
Participant 3, (White British, middle-aged, male) 
was looking for support with financial concerns 
and felt social prescribing was generally a good 
idea but would have liked more information 
about it. He said he had been waiting for 2 
months for a follow-up call from the SP service 
and had yet to progress to the final stage of the 
process (ie referral to community support or 
activity).  
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Participant 4, (White, middle-aged, male) was 
referred to the service to help with stress and 
anxiety. He found talking on the phone quite 
difficult and did not want to be referred on at the 
time. He would have liked more information 
about SP and felt that talking to someone 
properly, face-to-face would have helped. He also 
would have liked some support going to the 
referral organisation for the first time. He thinks 
SP is generally a good idea and wished he could 
have taken up the referral, he now feels as 
though he needs to ‘grin and bear it’ until he has 
the confidence to take first steps on his own. 
 
‘I (the call from the social prescriber) 
helped me at the time…but I need to 
actually see someone and sit and have a 
chat and explain my life and situation and 
then maybe they can put me on to 
someone who can help me out.’  
It’s confidence that I’ve lost...I feel like I’m 
useless.’ 
‘I would try it (social prescribing) again in 
future and would recommend it to others.’ 
 
Participant 5, (South American, elderly, female) 
she was lonely and wanted some support with 
finances and day-to-day life. While she was happy 
to use the phone, rather than face-to-face, she 
didn’t feel like the service had helped her and 
found the process very frustrating. 
 
‘Why bother me if they can’t help me?’ 
 
Participant 6, (Eastern European, middle-aged, 
female) presented with housing, unemployment 
and health issues. Could not get a coherent 
response to her experiences of the SP service but 
she was very unhappy about the health service in 
general. 
 
‘System is like the Gestapo - here to make 
you suffer.’ 
 
Participant 7, (White British, elderly, female) was 
referred for anxiety. Found the first contact with 
the SP team ‘pleasant’ and was referred to talking 
therapies. However, she could not attend 
because her anxiety prevented her from leaving 
the house and decided that talking about her 
problems would only make things worse. She 
thought SP could help others but she would have 
preferred a consultation with a counsellor. She is 
also looking into online therapy solutions 
independently. 
 
‘I don’t think it was for me personally but 
it could well help other people.’ 
 
Participant 8, (British, middle-aged, female) 
needed help with housing issues and also her 
daughter who is depressed. She had one call from 
the SP team and was expecting another but had 
not heard anything in the last three months. She 
thought social prescribers might have been able 
to help her but because she has not heard from 
them or been referred she doesn’t feel as though 
she has got anywhere. 
 
Participant 9, (Bangladeshi, late thirties, female) 
was referred to SP for help with her son’s 
benefits. The SP team made an appointment for 
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her with CAB, who she’d tried unsuccessfully to 
contact herself. A year later, the issue has been 
resolved and she was very happy with her 
experience of the social prescribing service. 
 
‘It (the SP service) was actually quite 
good.’ 
‘If I was on my own I would have to call 
and call and ask for help and I don’t know 
who to go to. If someone (the social 
prescriber) didn’t call me I would be 
struggling, you know, if they hadn’t called 
there would be so much stress about 
where to go.’ 
 
5.2.4 Interviews with stakeholders 
This section explores the strengths, challenges 
and lessons learnt by stakeholders involved in the 
development and implementation of the social 
prescribing pilot in the borough. We interviewed 
a mix of stakeholders including social prescribers, 
commissioners, healthcare professionals and 
community organisations delivering SP. We 
report the results from stakeholders below and 
discuss these in section 6.1.2.  
 
Interviews and focus group with social 
prescribers 
Social prescribers could really see the importance 
of providing a social prescribing service in the 
borough and were acutely aware of its potential 
to effectively support people to change their 
behaviour but also in finding ways to solve their 
complex problems. Social prescribers reported 
that there are advantages in providing a phone-
based service as some people find it easier to 
disclose personal information than through face-
to-face meetings due to the more informal means 
of communication. However, social prescribers 
were also aware of the importance of offering a 
face-to-face service particularly to those who 
present with more complex life situations and 
who are from marginalised and vulnerable 
groups. 
 
Work load was identified as one of the most 
relevant issues by the two social prescribers. 
Their job role involved contacting patients 
referred by healthcare professionals, finding 
relevant activities locally, connecting with the 
CVS, doing follow up calls, overseeing the 
telephone evaluation data collection, organising 
regular SP network and training meetings, 
feeding back to referrers, writing briefing reports 
and communication updates, and presenting to a 
wide group of stakeholders (including all the 
admin associated with these processes.) 
Maintaining a high and regular profile within the 
surgeries was found to help with referral 
numbers but this was hard to achieve with only 
two social prescribers.  
 
More than the anticipated three calls are being 
made to many individuals because people want 
to talk in detail about their issues or they present 
with more than one (often complex) issue. 
Patients are often not given enough information 
from referrers about what the social prescribing 
service involves (a telephone only signposting 
service) and the SP team then has to manage 
unrealistic expectations. For example, they 
expect social prescribers to solve their patient’s 
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housing problems or to provide an immediate 
befriending service for those who are frail, often 
housebound and socially isolated.  
 
‘Managing the expectations of GPs – they 
think you know everything that is going on out 
there. They think you can solve their patient’s 
problem with housing.’ 
‘Social isolation is the number one problem– 
people want a befriending service-there is only 
one and waiting list is 6 months for 
housebound.’ 
Social isolation is one area where there are 
inadequate resources available in the community 
as there is not enough befriending support 
available across the borough. This is a particular 
problem for those with specific language and 
cultural requirements. Other gaps in provision 
include services for the hard of hearing or those 
who speak little or no English. The 
comprehensive directory of services and 
voluntary organisations is still a work in progress 
so often referrers are unaware of other similar 
organisations nearby. In order to facilitate 
appropriate referrals in a context of limited 
community services available, social prescribers 
spend a significant amount of time trying to 
develop networks with and between community 
organisations.  
 
‘Introducing the voluntary sector to each other 
takes up time not allocated for. There is no 
directory of services.’   ‘I have been making it 
happen. I’m what a voluntary sector unit 
should be doing.’ 
Focus group, interviews and an online survey 
with the community and voluntary sector 
 
Three people participated to the focus group that 
was conducted by a UEL researcher in early 2017. 
Participants felt that the social prescribing has 
considerable potential in terms of providing 
‘holistic’ health care that joins up the community 
sector with primary care. Social prescribing is 
seen as a good way to provide residents with 
additional care options via the community sector. 
The current link with social prescribers was 
generally working well and it was of major help, 
particularly in referrals to the Citizen Advisory 
Bureau (CAB). In this case, social prescribing was 
seen as an important service to ‘filter’ relevant 
cases as most people need help with many 
disparate problems all happening at the same 
time. These include social isolation, housing, 
employment and mental health issues. The social 
prescriber was seen as useful for advising people 
where they can access help with their many 
disparate issues.  
 
For one of the respondents, previous pathways 
had broken down and social prescribing was 
replacing these with a service that increases 
collaboration between the community sector and 
the council and, in the future, with the CCG.  
 
One of the respondents pointed out that the 
community sector has traditionally found it 
difficult to establish links with GP practices 
directly. Social prescribing provides a vehicle for 
the council and the CCG to encourage GP 
practices to refer patients to the voluntary sector 
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via social prescribers which enables them to set 
up and develop links between primary care and 
the community sector. 
 
However, respondents highlighted some key 
challenges with the current model of social 
prescribing including the lack of resources, skills 
capacity of each organisation and the capacity of 
the sector as a whole. As one of the respondents 
pointed out:  
 
‘There is no money in the community 
sector. It is great that SP refers people to 
us but there are no enough people, we 
won’t be able to offer any services. 
[..]There is a real expectation that the 
community sector somehow kind of just 
can expand infinitely to take on someone 
else’s strategy and aims’.  
 
The lack of resources had a tangible impact on 
one of the respondent’s organisation who 
highlighted the fact that in the current funding 
climate they rely on social prescribers to contact 
and accompany SP service users to activities. As 
social prescribers are not providing this service, 
all the referrals to their organisations have not 
led to any user attending their activities and 
receiving support.  
 
An additional challenge respondents agreed upon 
was the set of skills required by local authorities 
and CCGs to apply for funding and work in 
partnership. Partnership working was welcomed 
by respondents but a combination of lack of time 
and skills seemed to prevent them from making 
effective use of available opportunities. One of 
the respondents called for more training in 
equipping voluntary organisations with the skills 
and knowledge to apply for funding.  
 
‘And there is not training that actually say 
oh let’s give organisations training on the 
key elements of partnership, no much 
capacity building. More hand holding and 
support.’ 
 
Finally, a third important challenge highlighted by 
a respondent was the need for the sector to 
include mid-range organisations and increase the 
variety of its offer. Respondents pointed out that 
on the one hand large voluntary organisations 
such as AGEUK operate in the borough, and on 
the other there are a sufficient number of 
grassroot organisations but not much in between. 
Furthermore, there are only limited specialist 
services such as mental health services, and other 
organisations have left the borough as funding is 
limited. The lack of specialist advice was also a 
problem in relation to CAB assistance where 
referrals significantly outnumbered the capacity 
on offer and the work of experts in housing and 
employment advice would be welcome.  
 
Online survey with community organisations: 
there were only 6 responses from community 
organisations at the time of writing but they 
represented a diverse range of support including: 
Talking Therapies, physical activities, housing and 
financial advice. All had received referrals from 
the social prescribing service and 5 out of 6 said 
these had been straightforward. One 
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organisation, however, complained that referrers 
had consistently failed to provide the information 
required for their referral form, creating extra 
work for them. Suggested improvements to the 
service included improved communication with 
GPs and better links with other organisations in 
the community. Signposting and professional 
referral received the most endorsement in terms 
of the role of the social prescriber; but one-to-
one coaching and buddying also received votes. 
Three organisations cross-referred users to other 
organisations, whilst two did not. Four of the six 
organisations provided some sort of feedback. 4 
of the organisations felt that social prescribing 
contributed to stronger links with the NHS and 
other organisations, 3 felt that it improved their 
attendance numbers. Concerns were expressed 
however, at the lack of extra funding for 
community organisations as a result. 
 
Key themes emerging from interviews with other 
stakeholders 
Some commissioners, and healthcare 
professionals were also interviewed to provide 
views about the strengths and challenges of 
social prescribing including the vision for its 
future. Overall, stakeholders pointed to a number 
of strengths of social prescribing. A clear 
emphasis was placed on the need to re-direct 
people to non-health resources, as a way to 
address social determinants of health. Social 
prescribing was also seen by respondents as a 
way to include the voluntary sector as an ‘asset’ 
in an effort towards improving the health and 
wellbeing of residents in the borough. Social 
prescribing offers the voluntary sector an 
opportunity to promote itself and offer services 
that respond more effectively to the needs of 
residents:  
 
‘Age UK are set up to literally treat 
everybody in the same way. If you are 60 
years old, you turn up at Age UK, you are 
offered the same service. Social 
prescribing will help realise that some 60 
years old behave differently and need 
something different from other 60 years 
old as there are a range of services 
available to choose from.’ 
 
Apart from being an advantage for voluntary 
organisations, social prescribing is also an 
opportunity for users of the service to reflect on 
what their needs and aspirations are alongside a 
social prescriber who can support them to choose 
from a range of services.  
 
An additional important strength for the 
development of social prescribing was identified 
by respondents as the commitment of social 
prescribers whom were seen as extremely 
motivated and effective in delivering the service 
and building the capacity of the voluntary sector 
to receive referrals, establish links between 
organisations and provide training. This resulted 
in new links set up with the voluntary sector and 
a small but increasingly widening support offer.  
 
Respondents also reported on a number of 
challenges including crucially the lack of capacity 
and resources of the voluntary sector, the lack of 
resource in the health and social care system as a 
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whole, and the higher than expected need of 
residents referred. Respondents mentioned that 
these challenges need to be seen as part of the 
learning associated with developing social 
prescribing as a new intervention. Any 
assessment of social prescribing should also be 
seen in the context of the wider sets of health 
interventions put in place in the borough through 
the Better Care Together Programme. As social 
prescribing was implemented more quickly than 
other interventions, the overall pathway and 
choice for residents referred by GP practices and 
other sources was not optimally utilised. Thus, an 
overall assessment of social prescribing needs to 
take into account of the fact that other 
interventions are not yet fully functional.  
 
Respondents highlighted the higher than 
expected rate of referral, high number of people 
with acute needs and the number of unmet 
needs. As SP users have greater needs, more time 
was spent to support them which led to the 
inability to support other residents and the 
accumulation of a backlog. One respondent 
pointed out that if other interventions such as 
Living Well Waltham Forest had been active, the 
backlog would have been partly addressed. The 
respondent continued by observing that social 
prescribers were never intended to support 
people with acute needs and a revision of the 
current service model is necessary.  
 
Regardless of these particular issues, all 
respondents agreed on the current inability of 
the voluntary sector to provide an appropriate 
non-clinical pathway for residents in the borough. 
Such inability was due to historical 
underinvestment in the sector, but also a lack of 
council’s belief in the potential of the sector.  
 
‘It is not clear how really interested the 
council is in supporting the voluntary 
sector. In other councils you have very 
strong strategies on how you are going to 
develop the voluntary sector. But here, to 
be honest, my impression is that it is not 
one of their strengths.’ 
 
And again, 
 
‘A lot of diagnostic work has been done in 
the last two years which has reached the 
same conclusion [that current size of the 
voluntary sector is not adequate].’ 
 
The voluntary sector also needs to be more 
creative in trying to find funding from other 
sources beyond local authorities. There has been 
an overreliance on local authority funding in the 
past. It was suggested that apart from providing 
more resources, the council could help further 
with business support and training provision 
which for some respondents has currently started 
to take place.  
 
‘There is a plan to have regular dialogue 
sessions, to undertake more co-production 
work and service design solutions with the 
voluntary sector. There things are 
happening now, we ask the CVS sector to 
co-design our service model, but they 
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would not have happened at the time 
when SP first went live.’ 
 
One respondent highlighted the need for greater 
clarity in policy development.  
 
‘We want the voluntary sector to deliver 
services, but we withdraw funding to 
them. A case of ‘cognitive dissonance’.’ 
 
Respondents felt that the future for social 
prescribing is uncertain. There are many 
competing demands particularly in relation to 
funding acute services in the CCG but politically 
both CCGs and local authorities, and the latter in 
particular, can see the benefits of social 
prescribing especially in relation to addressing 
the social determinants of health.  
 
One respondent clarified that social prescribing 
cannot request substantial new resources to be 
made available but needs to make use of existing 
resources in the system. 
 
‘The only really credible basis for a 
business case for SP in this borough which 
has many competing demands is if we are 
successful in weaving the frontline SP 
activity, team of frontline Social 
prescribers using existing resources’.  
 
On this basis, the future of social prescribing was 
seen as a clearer design of how social prescribing 
fits into the overall local health system. Social 
prescribers were seen as having a very strong 
understanding of the services available in the 
borough with excellent information at their 
fingertips primarily in the form of an integrated 
directory, operating a light touch signposting role 
and referring them to different frontline services 
depending on their needs. The respondent 
pointed out that the involvement of social 
prescribers in a signposting light touch role would 
ensure a high volume service and hence justify 
the investment.  
 
‘The idea of the social prescriber is to 
devise a care of package and support for 
that residents which will do the job. 
Motivate the patient to access care and 
support, to follow up on whether the 
resident has indeed made use of the care 
and support.’  
 
In order to achieve smooth functioning and 
support as many people as possible in the right 
way, one respondent discussed the provision of a 
‘universal training’ which would be made 
available to a spectrum of people working on the 
frontline in the delivery of social prescribing and 
its referral to community organisations.  
 
Online surveys with health professionals and 
community organisations: at the time of writing 
the report, 11 responses had been received from 
health care professionals via an online service 
evaluation survey. Respondents represented a 
variety of roles including a GP, social worker, 
nurses, physiotherapist, psychotherapist and 
administrator. Half of the respondents claimed to 
know quite well or very well what support was 
available in the community. However 10% (one 
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respondent) said they had no knowledge at all. A 
large proportion of respondents (80%) had 
referred to the service and nearly 90% said the 
process was straightforward. One commented, 
however, that it took a long time for the social 
prescribing team to contact the service user and 
they had to do a lot of chasing. Reasons for not 
referring were given as being uncertain about the 
service and forgetting that the service exists.  
 
The vast majority of healthcare professionals 
(90%) reported that one of the most beneficial 
aspects of social prescribing was its contribution 
to tackle social isolation. This was followed by 
improved mental health (50% of respondents) 
and housing (40%). 7 out of 11 respondents felt 
that support with social issues was the most 
beneficial aspect of social prescribing for 
clinicians although 2 felt it did not benefit them 
at all. 70% wanted to see the social prescribing 
service continue in Waltham Forest suggesting 
improvements to the service such as more 
information for service users and improving 
feedback channels for all involved. 
 
5.3 Economic evaluation and use of services: Social Return on Investment 
The Social Return on Investment analysis (SROI) is a staged process that considers the inputs, outputs and 
outcomes from the intervention and produces a financial assessment of the return to society given the 
initial investment (Cupitt, 2009). We make use of an established SROI analysis which accounts for 
displacement, attribution, deadweight, and drop off to generate a range of values in which SROI is likely to 
fall into.  
 
5.3.1 Mapping inputs  
The first part of the social return on investment considers the inputs which include the costs associated 
with setting up and running the intervention in Waltham Forest, whilst the final assessment will be 
available in the final report, after the collection of follow up data. The cost of running the SP intervention in 
Waltham Forest has been set to £128,000 for the first 12 month period April 2016 to end of March 2017. 
This is the cost to Waltham Forest council to run social prescribing including the cost of salaries, training 
and overheads. This does not include the cost to GP practices or community organisations supporting 
participants.  
 
5.3.2 Mapping outputs and outcomes 
Quantitative data have been used to inform this SROI. Baseline and four month follow up data from social 
prescribing users has been collected as part of the cohort study (sec 4.2.1).  Judgement has been made 
about what is measurable with the best approximation and what is in line with the aims of the evaluation.  
SROI assessments do not require the use of a control group as is the case for most economic evaluations. 
However, it does use a range of other strategies to establish the correct impact (sec.5.3.3 and 5.4.3) which 
include deadweight, attribution, displacement, drop off, and a sensitivity analysis accounting for different 
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options. We added a further element called net benefit calculation which accounts for the financial value of 
worsening health outcomes on respondents.  
 
Analysis of GP consultation rates 
A total of 32 SP users provided baseline and follow up data on the number of visits to GP in the four months 
prior to data collection. SP users recorded, on average, 2.25 fewer GP consultations four months after 
interventions in relation to four months prior to the intervention for a total of 72 fewer consultations and a 
saving to GPs of nearly £7.776. These only examine 32 completed cases. As fully functional social 
prescribing pilot support about 235 patients over a four month period (700 in one year), projections of 
savings in terms of GP costs could amount to nearly £20K over a four month period and £60K over a year. It 
is important to note that the calculation of these savings is only based on the cost of GP’s time rather than 
the GP practice as a whole (e.g. receptionist) or other costs (e.g. prescriptions), thus this is probably a gross 
underestimate of real cost benefit. On the other hand, there is no comparison group so it is difficult to 
estimate whether these benefits would have occurred anyway. 
 
Analysis of A&E attendance 
A total of 37 SP users provided baseline and follow up data on the number of visits to A&E in the four 
months prior to data collection. Mean A&E attendance at follow up was much higher than baseline (from 
an average of 0.27 to 0.62 visits). As the cost for A&E was calculated as £138 per patient per episode (DH, 
2016), this evaluation estimates a cost increase of £5,382 due to increased A&E attendance. We included 
different scenarios in the sensitivity analysis to account for attribution of A&E increase to the intervention.  
 
Volunteering  
SP users were asked whether and often they had volunteered in the three months prior to baseline and 
follow up data collection. At follow up they were asked if that was due to the referral from social 
prescribers. 13 SP users responded this question (n=50), two of whom started volunteering as a result of 
social prescribing, one respondent on a weekly basis, the other on a monthly basis. We estimate that each 
volunteer spent two hours volunteering each time they attended. In the three months prior to follow up 
data collection, their volunteering contribution is worth £292 to the organisations they supported. This was 
calculated at the living wage (£9.75 per hour in London). This is only for the period of data collection, so this 
data is likely to be significantly underestimated.   
 
Employment 
SP users were asked whether they found employment in the three months prior to follow up data 
collection. Three respondents had found employment. From a return on investment perspective, 
employment generates two types of benefit: a reduced burden on the Inland Revenue and an increased tax 
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payment. Assuming that all three respondents will be in full time employment for at least one year, the 
reduced burden on the Inland Revenue was calculated at £11,422 and the tax generated from a job paid at 
the living wage was £5,590. The total accrued was £17,012.  
 
Mental well-being 
SP users were asked   to complete the short version of the Warwick Edinburgh Mental Well-being Scale 
(SWEMWBS). This asks seven questions about aspects of the mental well-being.  In order to place a 
financial value on the outcomes from this tool, we compared it to the cost of low intensity IAPT treatment 
(Radhakrishnan et al 2013) which places a financial value of £493 per low intensity IAPT treatment.   39 
users responded this question at baseline and follow up, 24 (61%) of whom showed a benefit in the overall 
score, 14 experienced a decline in mental well-being over the period.  We calculated the net benefit i.e. 
those who received benefits minus those who experiencing a decline in mental well-being (total £4,930).  
 
Patient Activation Measure 
SP users were asked 13 questions about their level of activation at baseline and follow up through the 
Patient Activation Measure (PAM). Hibbard (2014) found that the annual cost differential between those 
high in Level 1 and those in Level 4 is £1,562 per patient. Following examination of the changes in PAM. We 
calculated net savings of £8,591.  
 
Quality of life 
We calculated how many respondents experienced changes in the five dimensions of quality of life drawing 
on the EQ-5D tool. We assessed positive and negative changes in mobility, usual activities, self-care, 
pain/discomfort and anxiety/depression and used established guidance from other SROI evaluations to cost 
each of these dimensions (Table 7).   
 
Table 7: Outputs and outcomes created by the social prescribing pilot in Waltham Forest 
Outcome  Data 
source 
Net change  Proxy and source Value (£) (net 
benefit over 
12 months **) 
Changes in GP 
consultation 
rates  
Cohort 
study 
72 fewer 
consultations 
£36 per consultation with General 
Practitioner (Curtis and Burns, 2016) 
£7,776  
Changes in A&E 
attendance 
Cohort 
study 
13 more A&E 
visits 
£138 per patient per episode (DH, 2016)   -£5,382 (*) 
Changes in 
Volunteering  
Cohort 
study 
2 volunteered Living wage in London (£9.75 per hour), 
2 hours per session per week 
£292  
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Change in 
employment  
Cohort 
study 
3 found 
employment 
Reduced burden to Inland Revenue 
(3,807.20 per person per year) 
https://www.gov. 
uk/jobseekersallowance/whatyoullget 
Tax generated:  
living wage per hour in London (£9.75) 
https://www.livingwage.org.uk/calculati
on 
£11,422+ 
£5590=17,012 
 
Mental well-
being  
Cohort 
study: 
SWEMW
BS 
10 improved 
MWB 
Cost per low intensity IAPT treatment is 
£493 (Radhakrishnan et al 2013) 
£4,930  
Level of 
Activation 
Cohort 
study: 
(PAM) 
22  £1,562 per patient annual cost 
differential between those high in Level 
1 and those in Level 4 (Hibbard, 2014) 
£8,591 
Mobility   
 
 
 
 
 
 
Cohort 
study: 
(EQ-5D, 
quality of 
life) 
48 (net 
benefit 
change is 3 
£3 per session, once per week.  
https://www.better.org.uk/leisure-
centre/london/waltham-forest/peter-
may-sports-centre/memberships 
 
£468 
Usual activities 48 (net 
benefit 
change is 17) 
Cost of social club membership and 
attendance at activities (£2 per session). 
Once per week 
£1,768 
Self-care  48 (net 
benefit 
change is 3) 
£480 per person managing yourself and 
person effectiveness training course 
£1,440 
 
Pain/discomfort 48 (net 
benefit 
change is 9) 
Average annual prescription per person 
in England (£142) 
https://www.nuffieldtrust.org.uk/chart/
annual-prescribing-spend-per-person-in-
the-uk 
 
£1,278 
Anxiety/depressi
on 
48 (net 
benefit 
change is 15) 
£45 per hour counselling (Curtis and 
Burns, 2016) 
£675 
(*) minus indicate an increased cost from baseline; (**) we calculated net benefits i.e. discounted 
respondents who saw their health or wellbeing decline over the period. 
 
 
5.3.3 Establishing impact  
In evaluating the Social Return on Investment is important to consider the effect of a number of elements 
including deadweight, displacement, attribution, drop-off, and net benefit calculation. Considering these 
elements helps to provide a more realistic and accurate assessment of SROI.  
Deadweight measures how much of the activity would have happened anyway. As most respondents had a 
very low level of activation at baseline and they required significant support to act upon their health and 
social issues, we estimate the deadweight to be nil.  
Attribution measures how much of the outcome was caused by the contribution of other organisations or 
people. Social prescribing is made of three key components including a referral source (e.g. GPs), the 
support work of social prescribers and the support work of community organisations. It is extremely 
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difficult to disentangle the contribution of each of these. In this SROI, we concentrate primarily on the work 
of social prescribers but we discount for the impact due to the work of community organisations. Our 
cohort study showed that only about 17 people attended community activities and 13 of these went to 
Citizen Advise Bureau (CAB) for reasons concerning mainly housing and employment. As a result, we 
accounted for the contribution of CAB by discounting the employment impact of social prescribing by 10% 
and the mental well-being and anxiety/depression by 5%.  
Displacement measures what activities or services are displaced by the project. Interviews with 
stakeholders revealed that social prescribing has been the only type of initiative available. Efforts to set up 
other similar initiatives which may have been displaced by social prescribing have taken longer and only 
recently been put in motion. As a result, we estimated a zero displacement. The work of social prescribers 
is primarily driven by the need to create a ‘non-existing’ link between primary care and the community 
sector therefore we estimated a nil displacement effect. 
Drop-off measures the decline in the outcome over time. The magnitude of the outcome generally reduces 
over time. It is generally calculated if the outcome lasts for more than one year and the annual rate of 
discount applied after this period is 3.5% (HM Treasury, 2003).  
Net benefit calculation: In this SROI we introduced a new element called ‘Net benefit calculation’. We have 
not observed this element in previous SROI on social prescribing and other areas (e.g. homelessness). We 
include it here as part of the evaluation and below in the sensitivity analysis. When exploring changes in 
mental wellbeing, quality of life and other health and social indicators, some SP users experienced positive 
changes i.e. they improved their quality of life or mental well-being, whilst others experienced a decline in 
the same indicators. We feel that if we attribute positive results to the effect of social prescribing, we also 
have to attribute negative results to the effect of social prescribing. So the financial values produced in this 
SROI account for net benefits (positive minus negative outcomes).  
 
5.4 Calculating the Social Return on Investment 
 
5.4.1 Establishing the present value (PV) 
During the SROI calculation, the ‘time value of money’ is usually recognised. This concept This concept is 
based on the idea that people prefer to receive money today as future payments are uncertain and 
alternative investment may be more convenient (Cupitt, 2009). In order to account for this, Table 7 shows 
the Present Value (PV) of estimated financial benefits has been discounted over the period of five years 
using a basic rate (r) of 3.5% (Treasury, 2003).  
 
Table 8: Value of impact over five years 
Year 1 2 3 4 5 
Impact       
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Present value = Impact in year 
1/(1+r) 
Impact in year 
2/(1+r)2 
Impact in year 
3/(1+r)3 
Impact in year 
4/(1+r)4 
Impact in year 
5/(1+r)5 
Present value 
for each year 
£35,619.86 £33,210.78 £30,964.64 £28,870.42 £26,917.83 
 
The total present value of social prescribing is £155,583.52 (the sum of third row Table 8).  
 
5.4.2 Calculating the Social Return on Investment (SROI) ratio 
The SROI ratio makes a comparison between the invested inputs and the financial value of the proposed 
outcome. The financial value of the former was calculated as £153,755 whilst the latter was obtained 
£155,583.52.  
Thus, the net SROI = £155,583.52   :  £ 128,000 
         = £1.22    : £1  
 
This ratio is the result of the financial calculation of SROI and the assumptions described 5.3.3 (deadweight, 
attrition, displacement, drop off and negative impact). However, good practice in SROI analysis dictates the 
selection of a range of values in which the ratio may fall into depending on a number of hypothesis. This 
range is examined in the section below (5.4.3). 
 
5.4.3 Sensitivity analysis 
The sensitivity analysis explores how SROI would change when assumptions about the impact of social 
prescribing are changed. It produces a range of possible ratios within which is realistic to expect SROI to fall 
into. We considered the following scenarios: 
Elimination of negative impacts cost assessment: As we considered positive health changes to respondents 
as due to the impact of social prescribing, we considered fair to discount the negative health outcomes as 
also due to lack of an impact of social prescribing. As a result we discounted the financial value due to 
negative health changes to respondents. However, SROI assessments do not place a financial value on 
negative health outcomes so we present here the SROI without such negative impacts. The added benefit 
in terms of SROI are £16,330 which lead to a SROI ratio of £1 invested, a return of £1.92.  
Lowering attribution: from data collected via our survey instrument, we were able to ask respondents 
whether their attendance to community activities was due to the referral from social prescribing or had 
taken place independently. In order to account for this, we added 10% of all HH outcomes as attributed to 
outside unaccounted factors. This changes the SROI to £1:£1.09.  
Lowering drop-offs: the estimated duration of outcomes may have been underestimated. For example, 
some health benefits will continue well beyond the five years period (e.g. mental health). In order to 
account for this, some of the drop off outcomes have been lowered by 10%. The resulting SROI is then the 
following: £1:£1.34. 
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5.4.4 Analysis of SROI 
Following the sensitivity analysis which takes into account of a range of additional factors influencing the 
value of outputs and outcomes, it is possible to generate a range within which the social return on 
investment for social prescribing in Waltham Forest is likely to fall. The SROI is likely to range between 
£1.09 to £1.92, thus for £1 invested in social prescribing, our social return on investment is likely to range 
between £1.09 (£0.09 higher than the initial investment) and £1.92 (£0.92 higher than the initial 
investment). This calculation is open to some limitations which are explored in the discussion section 
(6.1.3). 
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6 Discussion 
 
6.1 Summary of the main findings  
This section discusses the main findings in light of the four key aims of the evaluation 
 
6.1.1 The impact of the social prescribing pilot on the changes in patients’ health and social outcomes  
The majority of respondents in the sample were women (63%), only 21% were aged 65 or over, and from 
ethnically mixed background (44% white). A substantial proportion of the people in the sample lived alone 
(38%), were not in paid employment (65%), and unable to work due to sickness (33%). The make up of this 
population is slightly different from other social prescribing pilot which tend to target an older population 
(e.g. Kimberlee, 2016; Bertotti et al 2015), and have a large proportion of people in working age who are 
not in paid employment primarily because they are unable to work due to sickness.  
 
Given the large proportion of people who are not in employment and experiencing physical and/or mental 
health issues, it is not surprising that work and finances were their main concern, followed by physical and 
mental health. When looking at the changes that occurred during the evaluation period, most of the 
improvement in the concerns of respondents was related to housing, practical support and work/finance. 
In terms of their second concern, respondents reported the largest improvements in ‘practical support’ and 
‘mental health’. This shows that on average the intervention has somewhat helped respondents to address 
their housing, work/finance but has been less effective in relation to addressing mental and physical health 
problems.  
 
Another important finding of this evaluation is that respondents experienced positive changes in all health 
measures (general health, well-being, quality of life and mental well-being) and activation (patient 
activation measure) between baseline and four months follow up. Changes in well-being, quality of life and 
patient activation were also statistically significant which is particularly relevant given the short follow up of 
four months. It is reasonable to expect further improvements over a longer period as well-being and quality 
of life improvements can only generally be detected over a longer period (e.g. 1-2 years).  
 
Yet, it is also important to note that these positive benefits come from a very low starting position and 
seem to be only marginal, at least in relation to this follow up period. For example, mean changes in mental 
well-being between 18.3 and 19.2 is well below the mean of 24 (out of 35) that represent the average 
mental well-being of the UK (HSE, 2011) and other social prescribing pilots (Weld et al, 2015; Bertotti et al 
2014) but in line with another pilot (Brandling et al 2011).  
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In relation to levels of patient activation, statistically significant improvements were detected with 
considerable changes in level of activation from level 1 to level 2 and 3, although none to level 4. This 
means that almost 30% of the respondents moved from being ‘disengaged and overwhelmed’ to becoming 
‘aware, but still struggling’ (19%) and ‘taking action’ (11%), although none of the respondents were able to 
reach the level 4 status of ‘maintaining behaviour and pushing further’.  
 
In summary, these results should only be seen as a step toward a satisfactory health and well-being status 
rather than an end in itself. It appears that social prescribing is able to support people’s circumstances but 
such support needs to be maintained over time in order to create the basis for long lasting, more 
permanent health gains. From the point of view of perceived changes in participants’ concerns, a ‘triage’ 
style model of social prescribing and referral which focuses more on supporting respondents with complex 
psychological issues would be more effective than the current telephone system which, on its own, is 
unable to provide the required in-depth conversations between social prescribers and patients needed for 
effective referral to psychological and physical health support in the community or statutory sectors.  
Furthermore, health and patient activation gains could be further reinforced by expanding the links and 
offer of the CVS organisations operating in the borough. 
 
6.1.2 Development of the pilot and integration into wider health economy 
The referral target of 650 referrals to social prescribers is very likely to be exceeded within the set 
timescale (July 2016 - Dec 2017) as the current number of referrals received was 600 at the end of June 
2017. However, this does not represent the number of people who have been actually supported by the 
intervention but only the number of referrals to social prescribers from various sources, primarily GP 
practices. We suggest that a target number of people assisted by the social prescribers and referred on is 
set by the commissioners in consultation with social prescribers. This depends upon the specific model 
used i.e. more or less intense support provided face to face or by telephone only. An economic evidence 
review by Polley et al. (2017) shows that on average one social prescriber managed to provide in-depth 
support for 167 users over a 12 month period which makes 14 patients per month. This includes constant 
contact with GP practices and other referral sources to ensure a continuous flow of referrals, in-depth user 
support (at least 2-3 consultations) as well as establishing and maintaining contacts with community and 
statutory services for correct referral.  
 
Social prescribers were seen as key to the effective development of social prescribing. With the exception 
of some users, most other stakeholders (commissioners, healthcare professionals and community 
organisations) had an overwhelming positive opinion towards social prescribers. Social prescribers were 
highly regarded due to their person-centered skills, their vast knowledge of the community and voluntary 
sector and their ability to connect community groups with others in the local area. Their extensive 
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knowledge of local community projects is such that other frontline professionals and support organisations 
request social prescribers to provide information on existing current services for their own clients.  
 
However, the appropriate role for a social prescriber was contested. It ranged substantially from an in-
depth referral support role to a much light touch signposting role. For example, some respondents from 
community organisations felt that the social prescriber should in some circumstances (e.g. lack of mobility, 
specific mental health issues) visit patients’ homes and accompany them to community activities, at least 
the first time. In their opinion, community organisations do not have enough capacity to visit the homes of 
people referred through social prescribing. There are examples from across other areas of the UK (e.g. 
Rotherham; Wigan; Calderdale) that have included home visits in their social prescribing model (Dayson 
and Bashir, 2014; Windle et al., 2016) and evidence that this has increased take up from one fifth to half of 
clients (Windle et al., 2016). However, other stakeholders warned about the cost involved in funding such 
model and emphasised an approach based on social prescribers as covering a primarily signposting role. 
This role would be delivered only over the phone, make use of an integrated directory of services, and the 
sharing of care records which would enable social prescribers to check the situation of each resident in 
other care settings. In the future, social prescribers would then be able to refer patients to Living Well 
Waltham Forest, as well as self-care pharmacists and physician associates or CVS directly, depending on the 
needs of each patient referred. Thus, the future role of social prescribers is seen as one of signposting a 
high volume of patients.   
 
The majority of social prescribing users (seven out of nine) did not feel they had been helped by the service, 
either because they were still waiting to be contacted by a community organisation at the time of interview 
or had not received a referral from social prescribers. Some respondents were somewhat incoherent in 
their responses. This reflects the level of need and the complex interaction between social and health 
issues, particularly concerns with housing and finance alongside physical and mental health problems. Such 
mix of complex needs leads users to have a range of appointments with public sector support services and 
difficulties in remembering clearly who has helped them. As a result, almost all respondents were unsure 
about what social prescribing was. Although this problem has been highlighted by other evaluations of 
social prescribing (Bertotti et al. 2014; Brandling et al., 2011), in Waltham Forest this problem appears to be 
more pronounced as the service is only delivered over the phone, whilst most other social prescribing 
services are delivered face to face, providing users more space to remember the names and faces of social 
prescribers. 
 
Despite an overall negative opinion about the support received from the service, two respondents felt 
positive about their referral on to support in the community at the time of the call, but this had not been 
enough to overcome the psychological barriers they were experiencing and they had failed to attend. These 
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patients felt they would have benefitted from a face-to-face model of social prescribing and possibly 
someone to accompany them to their first appointment. Several other patients were also ‘too high 
threshold’ for social prescribing and needed more intensive support than the service could provide, 
suggesting the need for a more defined set of referral criteria. This also impacted negatively on patients 
when they became increasingly frustrated by the inability of the service to solve specific issues with 
housing, for example. 
 
Extent of referral integration: the integration of the social prescribing pathway in Waltham Forest depends 
upon the relationship between three key stakeholders: social prescribers, healthcare professionals and the 
community and voluntary sector (CVS). Only one of healthcare professionals surveyed (n=11) encountered 
any problems in referring patients to social prescribers. Moreover, there are no issues of low referrals, 
rather there are too many referrals to social prescribers and the latter cannot cope with it. Thus, the 
relationship between social prescribers and healthcare professionals seem to work well overall. However, 
one of the issues that was identified at this stage of the pathway was the excessively high health needs of 
some patients referred. In this case, patients needed to be referred to clinical treatment rather than social 
prescribing. In collaboration with GP practices, social prescribers could therefore develop clearer criteria 
that would avoid the referral of patients with acute health conditions and/or change the social prescribing 
delivery model to accommodate for people with such conditions.  
 
The integration between social prescribing and the community and voluntary sector (CVS) was very poor at 
the beginning of the project and still insufficient at the end of the project, despite the dedication of social 
prescribers to building links with the CVS to ensure collaboration in receiving referrals and increasing 
referral options available to SP users. Commissioners, social prescribers, and community sector 
respondents agreed that the capacity of the community and voluntary sector (CVS) in the borough needs to 
be improved significantly. Social prescribers found it difficult to find appropriate services for some of the 
clients because of the gap in provision in the community sector, particularly in relation to befriending for 
those with specific language or cultural requirements and services for the hard of hearing. This was echoed 
by responses from social prescriber users who complained about the lack of service availability with clear 
implications for the success of social prescribing. The current lack of capacity of the CVS sector was 
highlighted as an historical problem due to lack of investment over a number of years which could be now 
bridged by investing in greater links with existing organisations through developing training opportunities 
as well as commissioning services. Stakeholders across the spectrum reported that other councils in London 
have a more developed strategy to support the role of the voluntary sector, although some respondents 
reported that the attitude toward the voluntary sector is changing. Social prescribers started to create links 
between CVS and the social prescribing service, but more needs to be done through funding and training 
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opportunities as there are skill gaps in the capacity of each organisation, and the capacity of the sector as a 
whole.  
 
In addition to the lack of CVS capacity and funding, social prescribers were unable to cope with the large 
number of referrals from healthcare professionals because of the lack of an adequate supporting 
infrastructure at the time of delivery of social prescribing. Other initiatives (e.g. Living Well Waltham 
Forest) were not operational at the time social prescribing was launched and this limited somewhat the 
options of social prescribers. One stakeholder pointed out that the planned introduction of Living Well 
Waltham Forest as well as the involvement of self-care pharmacists and physician associates will help to 
integrate social prescribing with other independently funded health interventions and thus maximise the 
returns to social prescribing.  
 
6.1.3 The social return on investment (economic evaluation) 
The Social Return on Investment (SROI) is likely to range between £1.09 and £1.92, thus for £1 invested in 
social prescribing, our social return on investment is likely to range between £1.09 (£0.09 higher than the 
initial investment) and £1.92 (£0.92 higher than the initial investment). This range is lower than the average 
SROI for the sector which was calculated by Polley et al. (2017) at £2.3 for each £1 pound invested. This can 
be due to several reasons:  
 If monitoring data had been collected for the all period to June, the SROI might have been substantially 
more accurate and potentially higher. For example, more accurate data on the number of people in 
employment as a result of social prescribing would have had a substantial impact on the SROI. 
Employment often contributes to the SROI both in terms of tax revenue increases and welfare benefits 
savings (e.g. job seekers’ allowance).  
 It is important to note that this SROI is based on data on 48 respondents, 10% of the total number of 
people referred over the period. This makes the current SROI a large underestimate of the total but 
shows that even at this low level of responses the SROI is likely to be a good investment as even in the 
worst case scenario (£1:£1.09), the loss is minimal.  
 There are economies of scale effects due to the inclusion into the SROI calculation of a larger sample of 
respondents. This means that SROI tends to be higher when the intervention covers a higher number of 
users. Thus, if social prescribing were to be extended the ratio would increase, the larger the 
investment, the larger the return. 
 There are only four months between baseline and follow up data collection. Within this period, some 
outcomes such as mental health, patient activation, employment may not have yet materialised. This is 
likely to lead to an underestimation of the SROI. 
In conclusion, the SROI ratio seems to be acceptable for what is a pilot project subject to revision. More 
accurate data collection in the future may enable to obtain a higher SROI ratio, particularly in terms of 
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collecting data on potential number of social prescribing users taking up employment and volunteering and 
other outcomes of use of healthcare services (e.g. medicine use).  
 
6.2 Limitations of the evaluation 
This evaluation has a range of important limitations as follows:  
(i) The absence of a control group is a problem in this evaluation and all the evaluations of social 
prescribing except one (Grant et al. 2000). It is difficult to attribute change in health outcomes to the 
effect of the intervention without an appropriate control group to compare results to.  This is even a 
more important problem in evaluations of social prescribing as most participants experience very 
acute health problems and therefore are more likely than average to improve over time even without 
the support from the service (e.g. regression to the mean). The use of randomised controlled trials 
(RCT) is judged as the most rigorous way to assess the effectiveness of a health intervention. However, 
just on step down from the RCT on the scale of rigour, a matched controlled group design could be 
used to assess effectiveness (Craig et al., 2012). This is easier to develop as it follows policy cycles and 
often much less costly than an RCT.  
(ii) The follow up sample size for the intervention (n=49) is small for regression analysis, thus we were not 
able to carry out further analysis on the whether age, gender, ethnicity, employment status and 
education level affect results. 
(iii) There is considerable uncertainty about the ‘right’ follow up period when considering complex 
interventions such as SP and issues about the appropriate survey instruments to be used. A four 
month follow up period may underestimate the impact of some health outcomes which may appear 
much later. Thus, although this evaluation found positive statistically significant changes in some 
health outcomes, these are likely to be higher in the future. The impact of social prescribing may have 
been underestimated.  
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7 Conclusion 
The Waltham Forest Social Prescribing Service has had a positive and in some cases statistically significant 
impact on health changes, particularly in terms of well-being, quality of life and patient activation. 
However, health outcomes improved from a very low starting position and much more support needs to be 
provided to users in order to help them to reach a satisfactory level of health and well-being. Respondents 
also reported large improvements in their concerns toward Housing, Practical Support, Work & Finance. 
Although qualitative interviews with users were not so positive, this was mainly related to the lack of 
Community and Voluntary Sector (CVS) offer and long waiting times rather than an aversion to the idea of 
social prescribing. The Social Return On Investment (SROI) showed that for £1 invested in the social 
prescribing service in Waltham Forest, the expected return to society could be between £1.09 and £1.92. 
This is below the average of other SROI evaluations (£1:£2.3) but it is important to recognise that this is a 
pilot and even this lower return would justify the investment.  
 
Thus, there is little doubt that social prescribing has had a positive impact on participants at an acceptable 
cost, despite the issues with a lack of integration, funding and capacity in the community and voluntary 
sector, and the lack of support that was planned to come from other initiatives such as Living Well Waltham 
Forest.  However, in considering how to design the model going forward, it is worth reflecting on the 
following recommendations which may be useful in designing a robust and effective social prescribing 
model.  
 
7.1 Key recommendations  
1. No model of social prescribing is likely to work unless the CVS is well connected with social prescribing 
and people have an adequate range of services they can choose from and be referred to. Building 
further links and investing in the development of the community and voluntary sector (CVS) is 
therefore a priority. Funding for service delivery is a priority for the sector but other aspects are also 
important. Various stakeholders identified important gaps in service provision (e.g. befriending) and 
capacity issues that could be partly addressed by training in building skills within the sector (e.g. skills 
to apply for funding other than local authority funding). Lastly, CVS organisations should be 
encouraged to refer to each other. This would benefit patients and build links between organisations 
for mutual support.  
2. The current number of social prescribers appears to be inadequate in relation to the number of 
referrals received. A change in the current model is required to maximise the chances that social 
prescribers can sufficiently ‘activate’ people referred so that they take up referrals. Targets for social 
prescribers should be based on the number of people assisted and referred to CVS or other services 
rather than on referrals received by healthcare professionals. Social prescribers could make use of 
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MYCAW to identify and monitor the type and level of concerns patients have. This would ensure that 
the service is person-centred and responds directly to the needs and aspirations of the patient. It 
would also help to assess needs of each patient and refer accordingly (see point 3 below and sec. 7.2 
for a suggested model).  
3. SP has been more effective in tackling practical problems (Work & Finance) than low and medium 
mental health problems and issues of social isolation/loneliness. This requires further consideration as 
to the best social prescribing model to be implemented. One option would be to consider the use of 
face to face in-depth consultations with social prescribers for those requiring mental health and social 
isolation/loneliness support as this group needs to be supported to address the barriers (both physical 
and psychological) that often stand in the way of behaviour change. Evidence shows that behaviour 
change requires the social prescriber spending time to listen and motivate patients to take sustained 
action to improve their health. This cannot be done over the phone as individuals need to establish a 
rapport. Options could include the involvement of volunteers for some aspects of this support eg. 
accompanying the patient to their first session, but in-depth consultation requires people with 
motivational and coaching as well as social skills of empathy and a significant knowledge of services 
available in the borough both CVS and statutory. 
4. The integration of the service into other Better Care Together Programme should be discussed further. 
In particular, there is a danger that the use of self-care pharmacists and physician associates may 
prolong the pathway and leading patients to be ‘lost in the system’. Current evidence shows that a 
non-clinical approach to patient needs that prioritises skills such as the ability to listen empathically 
and build a collaborative relationship is of primary importance. This would potentially be lost if 
pharmacists and physicians were to be involved in supporting patients as their training is primarily 
clinical and their knowledge of CVS organisations available in their locality is not likely to be of high 
standard. 
5. Some referrals experienced acute health and mental health problems that are not suitable for social 
prescribing which is primarily designed to improve levels of self-care and self-management. There is a 
risk that some individuals experiencing acute health problems are not properly diagnosed which could  
adversely impact their health. As a result, thresholds for referral criteria should be clarified further so 
that healthcare professionals can refer appropriately.  
 
7.2 An alternative social prescribing model  
In order to build on the recommendations in sec. 7.1, we have designed an alternative social prescribing 
model that may aid further discussions between the funders of this report and other stakeholders. This 
evaluation identified that two broad groups of social prescribing users are referred to the service by 
healthcare professionals (see 5.1.2).  
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The first (group 1) faces practical issues (finance, housing and other practical support), the second (group 2) 
faces mild to moderate mental health issues (including isolation). In many cases, people may present with 
more than one issue so the SP model needs to be designed in a way that can support both of these groups. 
Following referral, an initial phone call by a social prescriber can establish patient’s primary and secondary 
concerns and refer them accordingly. The MYCAW is a person-centred tool that enables social prescribers 
to group different types of health and non-health concerns into categories that can be used to make sense 
of broader issues.  The key concerns of each individual can then be addressed in a person-centred way 
whilst monitoring referral over time. MYCAW is particularly useful in determining when mental health 
issues are the primary concern, requiring a more intensive approach, or a secondary concern related to 
problems such as finance or housing. In this situation mental health may improve anyway, as a result of 
successfully addressing the primary concern.  
 
The evaluation of SP in Waltham Forest has shown that social prescribers can support patients with 
practical issues (group 1) over the phone and refer them directly to community and support services (e.g. 
CAB) with no further need for immediate contact. However, the role of the social prescriber may involve a 
follow up phone call to ensure that the patient has received help and assist with potential other problems 
that may require further referral to other CVS organisations or statutory sector. If patients who have been 
helped with their practical issues still experience other problems (isolation/loneliness, or mild to moderate 
mental health problems), a more in-depth service should be proposed involving a face-to-face consultation 
service (e.g. up to four consultations) accompanied by home visits, where necessary. Equally, if during the 
first telephone conversation, the patient reveals to the social prescriber that the primary concern is about 
poor mental health and/or social isolation/loneliness (group 2), the patient should be referred to more 
intensive face to face support. Evidence shows that a face-to-face consultation is more effective at 
activating the user and improves outcomes and likelihood of attendance to community and statutory 
services. Both social prescribers and the more in-depth consultation service would require people with a 
specific set of skills including motivational and coaching training, empathic listening skills, and significant 
knowledge of the range and quality of CVS organisations available in the borough. Home visits could be 
carried out by volunteers (e.g. befrienders, buddying) managed by social prescribers or an externally 
contracted CVS organisations.  
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Figure 8: Suggested model of social prescribing for Waltham Forest 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GP practices 
Citizen Advice 
Bureau 
Adult and social 
care 
CAB
Others 
Initial telephone 
call by Social 
Prescribers 
Follow-up call 
(more support 
needed?) 
Face-to-face 
sessions (identify 
barriers to 
progression) 
Talking Therapies Mental health issues (Group 2) 
e.g. anxiety, depression, 
isolation/loneliness 
Practical issues (group 1) 
e.g. finance, housing, practical 
support 
Community and 
statutory services:  
- CAB 
- St Mungo’s 
- Talking Therapies 
- Significant Seam 
REFERRAL SOURCES INTERACTION WITH SOCIAL PRESCRIBER COMMUNITY & STATUTORY 
SERVICES 
49 | P a g e  
 
 
 
 
 
 
 
 
 
 
50 | P a g e  
 
8 References 
Bertotti M, Frostick C, Findlay G, Netuveli G, Tong J, Harden A, Renton A (UEL); Carnes D, Sohanpal R, Hull S (Queen 
Mary) (2015) ‘Social Prescribing: integrating GP and Community Assets for Health’, report commissioned by Health 
Foundation (shine award) 
 
Bertotti M, Watts P, Akhter I, Eselebor D (2014) ‘Changes in health outcomes in diabetic and pre-diabetic patients in 
Newham Community Prescribing Pilot Project; analysis of pre and post data’, Newham Clinical Commissioning Group, 
August 2014 
 
Brandling J, House W, Howitt D, Sansom A (2011) ‘New Routes: Pilot research project of a new social prescribing 
service provided in Keynsham’, Mental Health Research & Development Unit, Bristol 
 
Cabassa LJ, Gomes AP, Meyreles Q, Capitelli L, Younge R, Dragatsi D, Alvarez J, Nicasio A, Druss B, Lewis-Fernández R 
(2013). ‘Primary health care experiences of Hispanics with serious mental illness: a mixed-methods study’. 
Administration and Policy in Mental Health, 26 October. 
 
Cawston, P., (2011) ’Social Prescribing in very deprived areas’. British Journal of General Practice, 61 (586), 350. 
 
Craig, P., Cooper, C., Gunnell, D., Haw, S., Lawson, K., Macintyre, S., Ogilvie, D., Petticrew, M., Reeves, B., Sutton, M., 
Thompson, S., (2012) ‘Using natural experiments to evaluate population health interventions: new Medical Research 
Council guidance’, Journal of Epidemiology and Community Health, 66, 1182-1186. 
 
Cupitt, S. (Ed.). (2009) ‘A guide to social return on investment’. Cabinet Office, Office of the Third Sector. 
 
Curtis, L, Burns, A. (2016) ‘Unit Costs of Health and Social Care 2016’, Personal Social Services Research Unit, 
Canterbury, Kent. 
 
Dayson C and Bashir N (2014) ‘The social and economic impact of the Rotherham Social Prescribing Pilot’, Centre for 
Regional Economic and Social Research (CRESR), Sheffield University funded b NHS Rotherham Clinical Commissioning 
Group  
 
Department of Health, (2016) Reference costs 2015-2016, Department of Health  
 
Department of Health (2005) ’Supporting People with Long term conditions: An NHS and social care model to support 
local innovation and integration’. London: Department of Health. 
 
Department of Health (2013) ‘Improving quality of life for people with long term conditions’, available at 
https://www.gov.uk/government/policies/improving-quality-of-life-for-people-with-long-term-conditions. (accessed 
20.08.15). 
 
GP online (2014) ‘Health Secretary backs GP social prescribing’ by Neil Roberts  
 
Grant, C., Goodenough, T., Harvey, I. and Hine, C.(2000) ‘A randomized controlled trial and economic evaluation of a 
referrals facilitator between primary care and the voluntary sector’. BMJ, 320, 419–23. 
 
H M Treasury (2003) ‘The green book. Appraisal and evaluation in central government. The green book. Appraisal and 
evaluation in central government’, Her Majesty Treasury, London: TSO. 
 
Health Survey for England (2011) ‘SWEMWBS Population Norms in Health Survey for England data 2011’, 
http://www2.warwick.ac.uk/fac/med/research/platform/wemwbs/researchers/interpretations/wemwbs_population_
norms_in_health_survey_for_england_data_2011.pdf 
 
Hibbard, J and Gilburt, H (2014) ‘Supporting people to manage their health. An  introduction to patient activation’ , a 
report funded by the King’s Fund http://www.davidtredinnickmp.com/in-committee/ 
 
Hutt, P. and Gilmour, S. (2010) ‘Tackling inequalities in general practice’. The King’s Fund Research Paper. 
 
51 | P a g e  
 
Kimberlee, R (2016) ‘Gloucestershire  clinical commissioning groups social prescribing service: Evaluation report.’, 
University of West England, available  rom: http://eprints.uwe.ac.uk/30293  
 
Marmot, M., Allen, J., Goldblatt, P., Boyce, T., McNeish, D., Grady, M. and Geddes, I. (2010) ’Fair society, healthy lives: 
strategic review of health inequalities in England post 2010’. London: The Marmot Review. 
 
Naranjo JD and McKean JW (2001) ‘Adjusting for regression effect in uncontrolled studies’. Biometrics 57 (1):178-181 
 
National Health Service (2014) ‘Five Year forward view’. National Health Service. 
 
National Social Prescribing Network (2016) ‘Report of the annual social prescribing network conference’. 20th Jan 
2016, University of Westminster, Wellcome Trust, and Fit for Work UK Coalition with the support of the College of 
Medicine. 
 
Netuveli G, Wiggins RD, Montgomery SM, Hildon Z, Blane D (2008) ‘Mental health and resilience at older ages: 
bouncing back after adversity in the British Household Panel Survey’, Journal of epidemiology and community health 
62 (11):987-991. doi:10.1136/jech.2007.069138 
 
Polley, M.,  Bertotti, M., Kimberlee, R., Pilkington, K., and Refsum, C. (2017) ‘A Review of the evidence assessing 
impact of social prescribing in healthcare demand and cost implications’, a report commissioned by NHS England  
 
Putz R, O’Hara K, Taggart F, Sewart-Brown S (2012) ‘Using WEMWBS to measure the impact of your work on mental 
wellbeing: a practice=based user  guide’.  Feeling good and doing well in Coventry Wellbeing  
Project, Coventry City Council, Warwick Medical School, NHS Coventry 
 
Radhakrishnan, M., Hammond G., Jones, P.B., Watson, A., McMillan-Shields, F., Lafortune, L (2013) ‘Cost of Improving 
Access to Psychological Therapies (IAPWT) programme: An analysis of cost of session, treatment and recovery in 
selected Primary Care Trusts in the East of England region’, Behaviour Research and Therapy, 51, 37-45. 
 
Social Prescribing Network (2016) ‘Draft guidelines for NHS England’, unpublished document 
 
Tabrizi J, Wilson A, O’Rourke P (2010). ‘Customer quality and type 2 diabetes from the patients’ perspective: a cross-
sectional study’. Journal of Research in Health Sciences, vol 10, no 2, pp 69–76. 
 
Torjesen, I.(2016) ‘Social Prescribing could help alleviate pressure on GPs’, BMJ, http://dx.doi.org/10.1136/bmj.i1436) 
 
Weld, S., Kimberlee, R., Biggs, O., Blackburn, K., Clifford, Z. and Jones, M. (2015) ‘For All Healthy Living Centre’s 
Healthy Connections Project. Final evaluation report and Social Return on Investment (SROI) Analysis’.  Project report. 
UWE Bristol, Bristol. Available from: http://eprints.uwe.ac.uk/28427 
 
Windle, K., George, T., Porter, R., McKay, S., Culliney, M., Walker, J., Vos, J., Essam, N., Saunders, H. (2016) ‘Staying 
Well in Calderdale’ Programme Evaluation: Final Report. Lincoln, University of Lincoln. ISBN 978-1-86050-250-7.  
 
 
  
52 | P a g e  
 
 
9  Appendices 
 
9.1 Treatment effect analytical method 
The method explained in Netuveli et al. (2008) is used to analysis the treatment effect of SP on those 
continuous scores here. We first correct Y2 (score at follow up) for regression to the mean (RTM) effect 
using the method of Naranjo and McKean (2001): 𝑌2̂=𝑌2−((1−𝜌)(𝑌1− 𝜇)) where 𝑌2̂ is the corrected 
measurement at follow up, ρ is the correlation between Y1 and Y2 and μ is the common average for Y for 
both time points. In the second step we consider the change is real only if it is outside the 95% confidence 
interval of Y1. In regression based analyses, correction for RTM is easily achieved by including Y2 in the 
regression equation.  
 
9.2 Findings from qualitative interviews  
Table 9: Findings from qualitative interviews 
User concern (at time of 
interview) 
Process Outcome Demographics 
Homeless Referred by GP. 
SP referred her on to an organisation 
that could help. 
She was expecting to hear back from 
them but has heard nothing for 8 
weeks. 
Very unhappy with service. 
Doesn’t feel she has been 
helped. 
 
45-54yrs 
Caribbean 
Female 
Lives with others 
Unable to work (long 
term sickness) 
Left education age 16 
Financial help with 
prescription charges. 
Depression/anxiety/OCD. 
Referred by nurse?  Sarah from CAB? 
Had trouble filling out form – unclear 
whether questionnaire or prescription 
form! 
Thinks questionnaire was part of 
application for prescription charges. 
 
Helped her to get form to claim 
for prescription charges. 
Unclear whether help actually 
came through social 
prescribing. 
Waiting to hear back about 
application – could take 3 to 4 
months. 
Story not very coherent. 
45-54yrs 
Female 
Lives with others 
White British 
Looks after 
home/family 
Left education age 16 
Didn’t want to say. Referred by GP (he thinks!) 
Happy to talk on phone. 
Had one call so far but no follow-up 6 
weeks later. 
Waiting for next call, haven’t been 
referred on anywhere yet. 
 
Nothing’s come of it yet. 
Not sure whether SP suits him 
or not, needs more 
information. 
45-54yrs 
Male 
Lives alone 
White British 
Unable to work (long 
tem sickness) 
Left education age 16 
Lost confidence, stress 
and anxiety. 
Referred by a doctor at hospital. 
Would have liked more info. 
A week between referral and first call. 
Had two calls. 
Would have preferred face-to-face, 
phone quite difficult. 
Didn’t want referral at time. Thinks 
maybe he should have let them refer 
him on after all. 
 
 
Felt SP could help him. 
Relieved anxiety and stress by 
having someone to talk to (SP). 
Felt good after call but then 
things went back to normal. 
Face–to-face would have been 
a lot better for him. 
Someone to check out the 
organisation with him would 
have helped. 
Decided he’d rather deal with it 
himself and would ‘grin and 
bear it’.  
Found it helpful to certain 
extent but really he wanted to 
talk properly to someone face-
to-face. Would try SP again in 
future. 
Would recommend SP to 
others. 
55-64yrs 
Male 
Lives alone 
White British 
Unable to work (long 
term sickness) 
Left education age 12 
or less 
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Thinks he can get back on his 
feet by himself –the SP helped 
by giving him confidence to 
take those steps. 
Pension credit taken 
away. Very worried. 
Lonely – wants to know 
someone has her back. 
 
Doesn’t remember much about process. 
Two calls, she thinks. 
Preferred to speak over the phone but 
they couldn’t help her so it was a waste 
of time. 
 
They don’t help. Very 
frustrating. 
Would take a lot to change 
service for better. 
Would like some support from 
people to help her with day to 
day life.  
Asked about her pain ‘yes or 
no’ questions. Felt like another 
number to tick off. 
Doesn’t expect to hear from SP 
again. They listen and go. She 
nearly put phone down on 
them. Asked about illness but 
didn’t say they could do 
anything about it. 
75-84yrs 
Female 
Lives alone 
South American 
Retired from paid 
work 
Left education age 16 
Housing/ can’t work/ 
health? 
‘System is like the Gestapo – here to kill 
you.’ 
‘System here to make you suffer.’ 
‘Neglected and exploited by the 
government’. 
A social worker has helped her. 
 
Very unhappy about NHS, 
government and system in 
general 
Could not get coherent 
response about SP experience. 
45-54yrs 
Female 
Alone 
Lithuanian 
Unable to work (long 
term sickness) 
Left education at 
19yrs 
Anxiety Referred by social worker. 
Received some info on SP. 
A week between referral and first call. 
Phone contact was fine. SP was 
pleasant. 
Referred to talking therapy but didn’t 
attend. Decided later that she didn’t 
want to attend.  
More useful if someone could have 
come to her home (counsellor). 
 
Didn’t help her personally but 
could benefit others. 
Thinks it would be helpful for 
others but anxiety prevents her 
getting out. 
Involved travelling about which 
is not something she could do. 
Can only go as far as local 
shops – people don’t seem to 
understand. All outside, only 
wants to stay in. 
Found an online therapy 
solution by herself. 
65-74yrs old 
Female 
Lives alone 
White British 
Unable to work (long 
term sickness) 
Left education at 
16yrs 
Problem with getting 
daughter into school. 
Housing. 
Daughter depressed and 
self-harming. 
Referred by GP. 
Just one call from SP. Didn’t mind using 
phone. Was expecting them to call again 
but hasn’t heard anything in 3 months. 
No referral. 
Has tried standard housing routes but 
no joy because she’s not homeless. 
It helped to talk on the phone. 
Thought they might have been 
able to help but they haven’t 
called back. 
Doesn’t feel like she’s got 
anywhere. 
45-54yrs 
Female 
Lives with others 
British 
Looking after 
home/family 
Left education age 20 
or over 
Son’s benefits 
reduced/stopped. 
Tried unsuccessfully to contact CAB 
herself. 
SP made appointment with CAB for her. 
Can’t remember who referred her. 
3 calls in total from SP. 
Phone contact worked for her. 
Issue resolved (although took 1 
year). 
Happy with SP service. 
Would recommend to others. 
 
35-44yrs 
Female 
Lives with others 
Bangladeshi 
Unable to work (long 
term sickness) 
Left education age 16 
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9.3  Waltham Forest Social Prescribing Pathway (July 2016- Dec 2016) 
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